Regeneron Pharmaceuticals, Inc. - REGN
About Gravity Analytica
Recent News
- 10.28.2025 - Regeneron Pharmaceuticals Q3 2025 Earnings Conference Call
- 09.30.2025 - Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
- 09.26.2025 - Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
- 09.24.2025 - Bernstein Insights
- 09.22.2025 - Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
- 09.19.2025 - Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
- 09.17.2025 - Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
- 09.17.2025 - Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
- 09.09.2025 - Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
- 09.08.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference